About Trod Medical

Trod Medical is a Venture Capital backed privately held company focused on the development and commercialization of tools for use in the focal ablation of soft tissues. The company was founded in 2006 with initial in-vivo studies undertaken during 2007 and first in man studies were completed in 2010.

Trod Medical obtained a 510K clearance from the FDA in 2008 and a CE mark for its Encage™ Focal Ablation Device in 2015.

Vision

To be a leader in the field of focal therapy.

Mission

To delivercutting edge tools to facilitate the delivery of focal therapy supported by solid clinical evidence and customer support.



Paul Birkmeyer CEO and Director

Paul, an entrepreneur and executive in the medical device industry for 30 years, has served a range companies (large, small and startup) with innovative products in a variety of medical specialties including surgery and interventional technologies. His executive leadership and management experience spans all aspects of a life sciences company: worldwide product marketing, sales, technology, strategy, operations, clinical, and education. At startups, Paul collaborated successfully with MedTech investors and strategics, including exits and funding.

He has a record of accomplishments with best in class products. At Tyco Healthcare/Radionics, Paul played a pivotal role in helping establish a leading radiofrequency (RF) ablation device for liver cancer (MDT Cool-tip ® platform today), and separately commercialization leadership in RF pain management. At Johnson & Johnson/DePuy Spine, he developed with teams of surgeons and engineers, and then launched the company's first minimally-invasive (MIS) products, two of which reached market leading positions, in what is now a $3B MIS segment. At Johnson & Johnson, Paul assumed a corporate leadership role in market development and new technologies. He managed alliances and R&D relationships with multiple companies, including those in surgical navigation, robotics, and other technical platforms.

As President and Director at Ouroboros, Paul turned around this startup with a failed single product, and drove two new product programs that culminated in successful 2016 exits to both a market leader, and promising startup. His consulting work has had an impact on several innovative products. Paul separately serves on the board of Integrity Implants, Inc.

He has a Bachelor of Science in Electrical Engineering (BSEE) from the University of Connecticut, and a Master of Engineering in Engineering Management (MEM) from Dartmouth College (with novel program in management and engineering).







Dr. Christian Schneider

Dr. Christian Schneider is a Managing Partner of Vesalius Biocapital and has been a venture capital executive for the past 17 years. As a life science expert, he has extensive hands-on work and investment experience in the areas of diagnostics, medtech, and therapeutics. As shareholder and board member he actively supports and advices start-up companies.

Starting as an R&D scientist at Boehringer Mannheim / Roche (Tutzing/Penzberg, Germany, 1992-1995), he developed automated tests for the early detection of cancer. At Centocor (Malvern, Pennsylvania, USA, 1995-2000, sold to Johnson&Johnson for USD 5B in 1999), he led diagnostic product development in transatlantic collaborations. Later, as a business developer and external research manager in Centocor's / Johnson&Johnson's biological therapeutics business, he negotiated, financed, and managed international early-stage product development projects.

As a Managing Partner of venture capital firm PolyTechnos (Germany 2001-2008), he was directly responsible for the investments in and IPOs of OncoMethylome Sciences (Euronext, 2006), Devgen (Euronext, 2005) and Jerini (Frankfurt, 2005) and served as an independent director on the boards of Hepa Wash and MagnaMedics. In 2008, he joined the pan-European life science venture capital firm Vesalius Biocapital as a Managing Partner with responsibility for the investments and exits of Skyline (write-off) and Activaero (EUR 130m trade sale to Vectura, 2014). Across three Vesalius fund generations, he is currently responsible for portfolio companies Ventaleon, Omeicos, Humedics, Softhale and Mecuris.

Dr. Schneider holds a doctorate degree in veterinary medicine (1992) and a PhD in immunology (1995), both from the University of Munich, Germany, and an MBA in healthcare administration from Penn State University, Pennsylvania (1999).

Stephane Verdood

Stephane has an MBA and a Master's degree in commercial engineering from the Catholic University of Leuven.

Stephane is a recognized venture capitalist. He started his career with Arthur Andersen as information technology auditor. After having led the mergers and acquisitions division of Arthur Andersen in Belgium from 1989 to 1995, he founded and led Arthur Andersen's business consulting division in Belgium and Luxembourg. He served on the European Board of Partners of Arthur Andersen.

Since October 2000, before he joined Vesalius Biocapital, Stephane has been active as a venture coach for early-stage companies. He was a founder and managing partner at Value4Growth, a specialized Life Science consulting firm supporting start-up companies in all aspects of company formation, product strategy and fund raising.

Stephane is a founding partner of Vesalius Biocapital. Since 2007 he has invested in more than 15 biotech companies.

During his career he has worked in the US, Switzerland, France, the Netherlands, the UK and Portugal.

Michael Brock Chairman

Michael Brock has a Master Degree in Electronics engineering from Danish Technical University in 1979. Until the mid-nineties he was working with innovation and business development at Brüel&Kjær in Denmark - the global leader within sound and vibration measurements for industrial and environmental applications. In 1996, Michael became President & CEO of Madsen Electronics - a company within audiological measuring equipment - acquired several other related companies and finally founding a new consolidated company, Otometrics. In 2004 Michael became President & CEO for BK Medical - the global leader in the field of diagnostic ultrasound systems for urology - mainly prostate imaging - and surgery. During the years with BK Medical, Michael orchestrated a portfolio of innovative product launches enabling the company to grow significantly and thus consolidate its leading position in urology and prostate ultrasound. Since 2012 Michael has moved his career towards mainly board assignments, and he is today engaged in several companies in the medical field - hereunder as Chairman for Supersonic Imagine (Ultrasound Imaging, France) and DDD Diagnostic (Gamma Cameras, Denmark).